



## SARS-CoV-2 Serological Studies around the Globe

Guest Editors:

### **Prof. Dr. Angelos Hatzakis**

1. Department of Hygiene,  
Epidemiology and Medical  
Statistics, Medical School,  
National and Kapodistrian  
University of Athens, 11527  
Athens, Greece

2. Hellenic Scientific Society for  
the Study of AIDS, Sexually  
Transmitted and Emerging  
Diseases, 11527 Athens, Greece

### **Prof. Dr. Dimitrios Paraskevis**

Department of Hygiene,  
Epidemiology and Medical  
Statistics, School of Medicine,  
National and Kapodistrian  
University of Athens, 115 27  
Athens, Greece

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### **Message from the Guest Editors**

Dear Colleagues,

A novel coronavirus (2019-nCoV) associated with human to human transmission and severe human infection has been recently reported. Given the high transmissibility and the extensive geographic dispersal of the virus as well as the absence of effective treatments or a vaccine, public health measures provide the only way to prevent SARS-CoV-2 transmission. Given that SARS-CoV-2 is a new virus, we need to better understand the levels and the duration of protective immunity in patients with different severities of the disease (i.e., asymptomatic, mild and severe symptoms, hospitalized patients, ARDS symptoms), the levels of exposure to SARS-CoV-2 in highly vulnerable people and populations of special interest (i.e., healthcare workers, migrants, intravenous drug users, populations with limited access to health care facilities, HIV/AIDS patients), the parameters associated with the presence of antibodies, as well as the estimated performance of antibody testing in panels with known SARS-CoV-2 status. All of this information will be valuable across different geographic areas and different time periods.

Prof. Angelos Hatzakis

Dr. Dimitrios Paraskevis

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)